With activities in over 77 countries, our research heritage enables us to develop unique therapies and technologies that target Proteoglycan Atrophies and provide Proteoglycan Replacement Therapies that address a range of widespread dermatological disorders.
With a research heritage dating back to 1978, Pharma Medico has continuously invested in studying and documenting various pathologies related to human proteoglycan function.
From the early 1990’s we began developing therapies based on our research while continuously reinvesting in further research and development in our research centres in Scandinavia and the UK.
In the 2010’s, this led to global scientific recognition for our research work at large, including recognition of Proteoglycan Follicular Atrophy as a causal pathology for most hair loss and hair growth disorders.
Today, Pharma Medico’s research efforts are ongoing. As a manufacturer of pharmaceutical preparations and raw materials implemented in products, we are a top three global leader within our dermatological categories.
Pharma Medico Group operates globally, with an organisational structure composed of:
Our ethos underscores the importance of geographical representation in the countries and regions where we do business. This helps us to understand and quickly adapt to regulatory requirements, navigate and bridge cultural gaps, and respond to ever-evolving market conditions.
Our regional and national representations work closely with our local blue chip in-licensing and distribution partners, and the Group’s own national distribution entities.
These strategic partnerships extend our reach even further, and today, our therapies are available in over 500,000 commercial locations as well as in a multitude of major retail chains across the globe.
Through ongoing research and development, strong global partnerships, and proprietary and patented ingredients, products, and technologies, we are dedicated to improving quality of life for millions of people worldwide.
Dermatological disorders have life-altering effects on people all over the world.
For example:
These are widespread and can be not only physically challenging, but also psychologically and emotionally debilitating for self-esteem and self-perception.
Inducing well-being at all levels in the value chain.
Our vision at Pharma Medico Group is aimed at improving the life quality of people – and, to engender confidence and security wherever we operate over the long term.
To develop and market effective, clinically documented products with widespread appeal and high user loyalty.
Pharma Medico Group is founded on a strong Scandinavian tradition of research excellence and scientific documentation.
A commitment to well-being and sustainability through continuous improvement in all aspects.
Our values are firmly embedded throughout our daily operations as well as our vision for the future. Furthermore, we expect our partners, suppliers, and customers to recognise and practise these principles as a part of their own operations in a similar manner.
Our therapies include, among others, the globally recognised brands Nourkrin®, Nourella® and Zymbilan®, which are preferred by dermatologists, trichologists, and health care professionals as monotherapies and in combination with other products as add-on and adjunctive therapies.
Our therapies are developed through research into the role that proteoglycans, a glycoprotein vital for the structural and functional integrity of various tissues, play in the pathology of a wide range of dermatological disorders.
Our patented production process enables us to produce proprietary delivery technologies that optimise absorption and digestion to maximise bioavailability and efficacy.
Because our therapies are biologically active, they can be used on a long-term basis, and they address not only symptoms but help to restore biological balance and normal biological function.
Addresses Proteoglycan Follicular Atrophy
Provides Proteoglycan Replacement Therapy and next generation retinoid treatment for skin repair and rejuvenation
Addresses Epidermal Dysglycania and chronic inflammatory skin diseases
Proteoglycan Replacement Therapy (PRT) is today widely accepted in medical literature and clinical practice to help address Proteoglycan Follicular Atrophy, a root cause of diseases such as male and female alopecia, as well as Epidermal Dysglycania, a common condition in age and sun-damaged skin, psoriasis, eczema, and dermatitis.
Promising steps are also being made in our research pipeline toward documenting Proteoglycan Replacement Therapies that address other conditions like:
Our coordination offices were built in 1883 and are listed by the Danish Agency for Culture.
The building is closely linked to the city of Aarhus’ and Denmark’s history of social and civic responsibility and its global mercantile ambitions.
We collaborate with established distribution networks that reflect our dedication and core values.
If your organisation meets these criteria and offers something unique, we invite you to present your case. However, due to the high volume of inquiries, only those with compelling proposals and proven track records will be considered.
